Cargando…

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karbiener, Michael, Farcet, Maria R., Zollner, Andreas, Masuda, Taisei, Mori, Mitsuhiro, Moschen, Alexander R., Kreil, Thomas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857217/ https://www.ncbi.nlm.nih.gov/pubmed/35181655 http://dx.doi.org/10.1038/s41541-022-00455-3

Ejemplares similares

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic
por: Schwaiger, Julia, et al.
Publicado: (2020)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
por: Farcet, Maria R., et al.
Publicado: (2022)

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )
por: Farcet, Maria R, et al.
Publicado: (2022)

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
por: Karbiener, Michael, et al.
Publicado: (2021)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Longitudinal analysis of SARS‐CoV‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
por: Karbiener, Michael, et al.
Publicado: (2021)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Orthopox viruses and the safety margins of solvent‐detergent treated plasma‐derived medicinal products
por: Kindermann, Johanna, et al.
Publicado: (2022)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

Antibody‐enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin
por: Kapsch, Anna‐Maria, et al.
Publicado: (2020)

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19
por: Zollner, Andreas, et al.
Publicado: (2021)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Neutralizing Antibodies against SARS-CoV-2 and HLA Class I and II Polymorphism
por: Weidner, Lisa, et al.
Publicado: (2021)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

SARS-CoV-2 and the safety margins of cell-based biological medicinal products
por: Modrof, Jens, et al.
Publicado: (2020)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
por: Wagner, Angelika, et al.
Publicado: (2021)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants
por: Zhang, Jason Z., et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis
por: Sharma, Pragya, et al.
Publicado: (2022)

Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults
por: Jonsdottir, Hulda R., et al.
Publicado: (2021)

High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
por: Sasaki, Hiroaki, et al.
Publicado: (2022)

Preventing escape from neutralizing antibodies
por: Brown, Matthew
Publicado: (2020)

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
por: Funakoshi, Yohei, et al.
Publicado: (2022)

A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection
por: Springer, David Niklas, et al.
Publicado: (2023)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
por: Shurrab, Farah M., et al.
Publicado: (2022)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
por: Giuliano, Anna R., et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
por: Masuda, Taisei, et al.
Publicado: (2022)

Neutralizing antibody response in mild COVID-19
por: van der Heide, Verena
Publicado: (2020)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
por: Haberland, Annekathrin, et al.
Publicado: (2021)

SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
por: Aguilera, Ximena, et al.
Publicado: (2022)

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine
por: Furukawa, Koichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emuep0qftukis45ro50l7bqrc5